Medicare Adds Wegovy and Zepbound. Who’s Next?
Cash-pay options will get cheaper as private insurers weigh costs for coverage.
Eli Lilly’s Zepbound is one of the medications included in the Medicare deal.
Photographer: Bloomberg
Injectable weight-loss drugs have been a game changer for many Americans with obesity. The challenge has been getting a prescription and figuring out how to pay for it. That’s why an agreement announced last week to allow them for some Medicare patients is a big deal. Health reporter Madison Muller writes today about how it might affect the market overall. (Madison also has a story in Businessweek today about the sagging Botox empire.) Plus: China is pushing for a baby boom, Russian poachers are taking away trademarks, and a Korean comic company is adding American characters.
If this email was forwarded to you, click here to sign up.